Global funding activity across the life sciences sector was mixed in 2025. Venture capital (VC) activity was slightly higher, while the initial public offering (IPO) market experienced a down year. M&A deals accelerated sharply as pharmaceutical companies increased acquisition activity. Investor sentiment weighed on funding early in the year but improved meaningfully in the second half, driving a pickup in activity and signaling stronger momentum heading into 2026. READ MORE
Street Address
City, State, Zip
770-315-6331
executive compensation - venture capital - news
Your Custom Text Here